Abstract
IntroductionPhyllodes tumors are rare fibroepithelial lesions, with an incidence of 2.1 cases per million. They represent 0.2–2% of all breast tumors. The breast tumor department treats the largest number of patients per year at the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute, representing 17.4% of all patients treated in this centre. Material and methodsRetrospective, descriptive study. We assessed clinical and pathological characteristics, recurrences and overall survival at 5 years in patients with phyllodes tumor of the breast treated at the Oncology Hospital, Siglo XXI National Medical Center, from January 2000 to December 2017. ResultsThirty-two patients were included in the analysis. Mean age was 43.5 years, presentation was in the right breast in 66% of the patients and pain was present in 19%. 66% presented in the right breast, presented pain 19%. A total of 41% were benign phyllodes tumors, 41% were borderline and 18% malignant. In all, 18% of the cases were treated with wide resection, 65% with simple total mastectomy and 15% with modified radical mastectomy. Recurrence at 5 years was observed in 12%. Overall survival at 5 years was 94%, 100% for patients with benign histology, 100% for patients with borderline histology, and 66% for those with malignant histology (p=0.09). ConclusionsIn our population, phyllodes tumors show a tendency towards size greater than 5cm, which is reflected in the greater number of mastectomies in contrast to other reports.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.